Tufts CSDD Study Assessing the Financial Benefits of Translational PharmaceuticsÂ®: A Platform for Accelerating Product Development
Sponsored by: Quotient Sciences
- Formulation Development
- Clinical Trial Manufacturing
- Drug Product Manufacturing
Date: 22 January
Time: 10AM London
The drug development process has been demonstrated to be highly costly, lengthy, and risky with significant rates of molecule attrition. Despite long-standing efforts by drug developers to operate more efficiently, traditional drug development programs have become costlier on average. To inform drug developers of the potential financial impacts of alternative drug development processes and outsourcing models, the Tufts CSDD conducted a study comparing traditional drug development programs to Quotient Sciences’ signature drug product manufacturing and clinical testing platform, referred to as Translational Pharmaceutics. Translational Pharmaceutics is a unique platform which integrates formulation development, manufacturing and clinical testing and has been widely used by pharmaceutical and biotech companies to accelerate product development across the full development cycle. Key applications of Translational Pharmaceutics include the transition of molecules from First in Human (FIH) to Proof of Concept (POC), and in the development and optimization of clinical formulations including modified release (MR) drug products and solubility enhanced dosage forms. This webinar will summarize the key findings of the Tufts CSDD research on Translational Pharmaceutics, which includes mean time savings of >12 months and financial gains of >$100 million per drug approved.
Dr. Peter Scholes,
Chief Scientific Officer at Quotient Sciences
Peter has over 25 years’ experience in the pharmaceutical industry. In his role at Quotient Sciences he has been instrumental in identifying and implementing the innovative and flexible benefits of integrating pharmaceutical development and clinical testing in early research. Peter has served as a committee member for the U.K. Controlled Release Society and APS Biopharmaceutics focus group and in 2010 was named one of PharmaVOICE’s 100 most inspiring people in the life-sciences industry. He was appointed as an Honorary Professor in Pharmaceutical Sciences at Nottingham University in August 2015.
Dr. Joseph DiMasi,
Director of Economic Analysis at Tufts University
Dr. DiMasi's area of expertise is in R&D efficiency, approval success rates, development and regulatory approval time metrics, impact of regulatory policies, economics of innovation in the pharmaceutical and biotechnology industries. Dr. DiMasi's research interests include the R&D cost of new drug development, clinical success and phase attrition rates, development and regulatory approval times, the role that pharmacoeconomic evaluations have played in the R&D process, pricing and profitability in the pharmaceutical industry, innovation incentives for pharmaceutical R&D, and changes in the structure and performance of the pharmaceutical and biotechnology industries.
Key Learning Objectives
- Overview of the Translational Pharmaceutics platform; What is it and how is it different to traditional drug development?
- Summary of the Tufts CSDD White Paper: A review of the methodology, results and key conclusions â€“ time and cost savings
- Case studies to demonstrate when Translational Pharmaceutics can be utilised during drug development
- Formulation Development
- Drug Product Manufacturers
- Research & Development
- Program Management
- C level
- VP level
- Director level
- Drug Development